中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Mysterious alpha 6-containing nAChRs: function, pharmacology, and pathophysiology

文献类型:期刊论文

作者Yang, Ke-chun1,2; Jin, Guo-zhang1; Wu, Jie2
刊名ACTA PHARMACOLOGICA SINICA
出版日期2009-06
卷号30期号:6页码:740-751
关键词alpha 6-nicotinic acetylcholine receptor dopaminergic neuron alpha-conotoxin nicotine reinforcement Parkinson's disease
ISSN号1671-4083
DOI10.1038/aps.2009.63
文献子类Review
英文摘要Neuronal nicotinic acetylcholine receptors (nAChRs) are the superfamily of ligand-gated ion channels and widely expressed throughout the central and peripheral nervous systems. nAChRs play crucial roles in modulating a wide range of higher cognitive functions by mediating presynaptic, postsynaptic, and extrasynaptic signaling. Thus far, nine alpha (alpha 2-alpha 10) and three beta (beta 2, beta 3, and beta 4) subunits have been identified in the CNS, and these subunits assemble to form a diversity of functional nAChRs. Although alpha 4 beta 2- and alpha 7-nAChRs are the two major functional nAChR types in the CNS, alpha 6*-nAChRs are abundantly expressed in the midbrain dopaminergic (DAergic) system, including mesocorticolimbic and nigrostriatal pathways, and particularly present in presynaptic nerve terminals. Recently, functional and pharmacological profiles of alpha 6*-nAChRs have been assessed with the use of alpha 6 subunit blockers such as alpha-conotoxin MII and PIA, and also by using alpha 6 subunit knockout mice. By modulating DA release in the nucleus accumbens (NAc) and modulating GABA release onto DAergic neurons in the ventral tegmental area (VTA), alpha 6*-nAChRs may play important roles in the mediation of nicotine reward and addiction. Furthermore, alpha 6*-nAChRs in the nigrostriatal DAergic system may be promising targets for selective preventative treatment of Parkinson's disease (PD). Thus, alpha 6*-nAChRs may hold promise for future clinical treatment of human disorders, such as nicotine addiction and PD. In this review, we mainly focus on the recent advances in the understanding of alpha 6*-nAChR function, pharmacology and pathophysiology.
WOS关键词NICOTINIC ACETYLCHOLINE-RECEPTORS ; VENTRAL TEGMENTAL AREA ; ALPHA-CONOTOXIN-MII ; PARKINSONS-DISEASE STRIATUM ; MIDBRAIN DOPAMINE NEURONS ; HIGH-CALCIUM PERMEABILITY ; BRAIN REWARD AREAS ; SUBUNIT COMPOSITION ; NIGROSTRIATAL DAMAGE ; NUCLEUS-ACCUMBENS
资助项目Arizona Biomedical Research Commission[0028] ; Arizona Biomedical Research Commission[0057] ; Institute for Mental Health Research[00000000] ; Philip Morris International[2005-2008] ; Philip Morris International[2007-2010]
WOS研究方向Chemistry ; Pharmacology & Pharmacy
语种英语
CSCD记录号CSCD:3628647
WOS记录号WOS:000266916900010
出版者ACTA PHARMACOLOGICA SINICA
源URL[http://119.78.100.183/handle/2S10ELR8/279217]  
专题院士及顾问专家
通讯作者Wu, Jie
作者单位1.Chinese Acad Sci, Dept Pharmacol, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
2.St Josephs Hosp, Div Neurol, Barrow Neurol Inst, Phoenix, AZ 85013 USA;
推荐引用方式
GB/T 7714
Yang, Ke-chun,Jin, Guo-zhang,Wu, Jie. Mysterious alpha 6-containing nAChRs: function, pharmacology, and pathophysiology[J]. ACTA PHARMACOLOGICA SINICA,2009,30(6):740-751.
APA Yang, Ke-chun,Jin, Guo-zhang,&Wu, Jie.(2009).Mysterious alpha 6-containing nAChRs: function, pharmacology, and pathophysiology.ACTA PHARMACOLOGICA SINICA,30(6),740-751.
MLA Yang, Ke-chun,et al."Mysterious alpha 6-containing nAChRs: function, pharmacology, and pathophysiology".ACTA PHARMACOLOGICA SINICA 30.6(2009):740-751.

入库方式: OAI收割

来源:上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。